PKD2 and autosomal dominant polycystic kidney disease: We provide prioritized drug repurposing candidates predicted to reverse the ADPKD molecular phenotype that we identified in-silico by transcriptomic signature reversion of publicly available pre-cystic Pkd2 ADPKD mouse model RNA-seq data.